Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyureaAlberto Álvarez‐Larrán, Regina García, Valentín García‐Gutiérrez et al.|Cancer|2022Cited by 32
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreTiziano Barbui, Alessandro M. Vannucchi, Arianna Ghirardi et al.|Blood Cancer Journal|2022Cited by 14
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosisAlberto Hernández‐Sánchez, Á. Villaverde-Ramiro, Eduardo Arellano‐Rodrigo et al.|American Journal of Hematology|2024Cited by 8
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosisAdrián Mosquera Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote et al.|HemaSphere|2024Cited by 6
The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary MyelofibrosisTiziano Barbui, Björn Andréasson, Alessandra Carobbio et al.|Blood|2021Cited by 2